J. Roth

发表

p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.

T. Mukhopadhyay, J. Roth, 1996, Anticancer research.

The Relationship of Perceived Risk and Biases in Perceived Risk to Fracture Prevention Behavior in Older Women

A. LaCroix, J. Roth, D. Scholes, 2015, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Josh J. Carlson, Joshua A. Roth, J. Roth, 2013, Breast Cancer Research and Treatment.

Value and affordability of CAR T-cell therapy in the United States

S. Ramsey, C. Turtle, J. Roth, 2020, Bone Marrow Transplantation.

Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting

D. Boudreau, J. Roth, D. Veenstra, 2015, Pharmacoepidemiology and drug safety.

Exercise testing in the evaluation of patients at high risk for complications from lung resection.

R. Morice, J. Roth, J. Putnam, 1992, Chest.

Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic

S. Ramsey, J. Roth, J. Inadomi, 2021, JAMA network open.

Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial

J. Manson, Ruth Etzioni, Karen C Johnson, 2014, Annals of Internal Medicine.

A qualitative study exploring why individuals opt out of lung cancer screening

D. Buist, J. Roth, K. Wernli, 2017, Family practice.

Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing.

T. deVos, S. Ramsey, J. Roth, 2019, American health & drug benefits.

THE PROGNOSTIC ROLE OF ERCC1 IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW & META-ANALYSIS

J. Roth, J. Carlson, 2011 .

Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.

S. Ramsey, M. Bensink, J. Roth, 2014, Journal of comparative effectiveness research.

Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis

J. Roth, A. Basu, B. Devine, 2022, PharmacoEconomics - Open.

Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer

J. Roth, J. Sussell, C. Meyer, 2022, Advances in Therapy.

Low-dose computed tomography lung cancer screening in the Medicare program: Projected clinical, resource, and budget impact.

S. Ramsey, S. Sullivan, J. Roth, 2014 .

Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

J. Roth, J. Carlson, 2011, Clinical lung cancer.

A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective.

A. Caughey, J. Roth, Alyssa R. Hersh, 2021, JAMA pediatrics.

Genetic Risk Factors for Major Bleeding in Patients Treated With Warfarin in a Community Setting

D. Boudreau, M. Fujii, A. Rettie, 2014, Clinical pharmacology and therapeutics.

Health State Utilities Values For Post-Menopausal Women From The Women's Health Initiative Estrogen+Progestin Clincial Trial

G. Anderson, S. Ramsey, J. Roth, 2013 .

Isolation of total RNA from tissues or cell lines. Visualization in gel.

T. Mukhopadhyay, J. Roth, 1998, Methods in molecular biology.

Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes.

L. Matrisian, Ziding Feng, S. Chari, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis

J. Roth, A. Basu, B. Devine, 2022, PharmacoEconomics - Open.

PS3-4: Genetic Risk Factors for Major Bleeding in Warfarin Patients in a Community Setting

D. Boudreau, M. Fujii, A. Rettie, 2013, Clinical Medicine & Research.

The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative

G. Anderson, R. Chlebowski, J. Roth, 2020, Breast Cancer Research and Treatment.

Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer

J. Roth, J. Carlson, 2012, Journal of Gastrointestinal Cancer.

Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN).

Parth D. Shah, D. Patrick, R. Herbst, 2021, JCO Oncology Practice.

Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.

S. Ramsey, J. Roth, J. Carlson, 2015, The oncologist.

Silicone lubricant enhances recovery of nucleic acids after phenol-chloroform extraction.

T. Mukhopadhyay, J. Roth, 1993, Nucleic acids research.

Antisense therapy for cancer.

T. Mukhopadhyay, J. Roth, T Mukhopadhyay, 1995, The cancer journal from Scientific American.

A Formal Risk-benefit Framework for Genomic Tests: Facilitating the Appropriate Translation of Genomics into Clinical Practice

L. Garrison, S. Ramsey, W. Burke, 2022 .

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.

J. Roth, L. Steuten, M. Flanagan, 2019, Journal of managed care & specialty pharmacy.

The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature

T. Clemons, J. Roth, A. Basu, 2021, PharmacoEconomics (Auckland).

Antisense regulation of oncogenes in human cancer.

J. Roth, T. Mukhopadhyay, J. Roth, 1996, Critical reviews in oncogenesis.

Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma.

J. Roth, S. Maxwell, T. Mukhopadhyay, 1995, Oncogene.

Safety and Costs of Endobronchial Ultrasound-Guided Nodal Aspiration and Mediastinoscopy.

D. Wood, J. Roth, D. Francis, 2020, Chest.

Stakeholder Perspectives on a Risk-Benefit Framework for Genetic Testing

S. Ramsey, W. Burke, J. Roth, 2010, Public Health Genomics.

Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies

M. Cooperberg, Ruth Etzioni, J. Gore, 2022 .

Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare.

S. Ramsey, S. Sullivan, J. Roth, 2015, Journal of oncology practice.

Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.

S. Ramsey, J. Roth, J. Carlson, 2014, The oncologist.

263PSurvival gains from advances in first-line systemic therapy for HER2-positive metastatic breast cancer in the U.S., 1995-2015

S. Ramsey, S. Sullivan, J. Roth, 2017 .

A qualitative study exploring patient motivations for screening for lung cancer

D. Buist, J. Roth, K. Wernli, 2018, PloS one.

Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries

J. Roth, Shilpen A. Patel, J. McDougall, 2019, PloS one.

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States

S. Ramsey, S. Sullivan, J. Roth, 2018, Journal of medical economics.

Translating an Economic Analysis into a Tool for Public Health Resource Allocation in Cancer Survivorship

S. Ramsey, J. Roth, L. Richardson, 2023, MDM policy & practice.

Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.

J. Roth, A. Basu, B. Devine, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.

D. Boudreau, J. Roth, D. Veenstra, 2017, The American journal of medicine.

Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.

S. Ramsey, J. Roth, A. Ravelo, 2017, The oncologist.

A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer

S. Ramsey, J. Roth, M. Othus, 2020, Journal of medical economics.

The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups.

J. Manson, R. Chlebowski, J. Roth, 2020, Menopause.

A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice

L. Garrison, S. Ramsey, W. Burke, 2010, Genetics in Medicine.

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States

S. Ramsey, S. Sullivan, J. Roth, 2018, Journal of medical economics.